Literature DB >> 3202966

Enzymatically active cathepsin B dissociating from its inhibitor complexes is elevated in blood plasma of patients with septic shock and some malignant tumors.

I Assfalg-Machleidt1, M Jochum, W Klaubert, D Inthorn, W Machleidt.   

Abstract

Using fluorogenic substrates and the specific inhibitor E-64, cysteine proteinase (CP) activity was measured in blood plasma of healthy controls (mean = 35.0 mU/l) and patients with cancer and severe septic shock. Whereas moderately elevated activity was observed in some kinds of cancer (mean = 63.9 mU/l), 10-fold increased CP activity was found in septic shock. The plasma CP activity of sepsis patients paralleled the immunologically determined concentration of elastase-alpha 1-proteinase inhibitor complex. On the basis of its substrate specificity and its Michaelis constant for Z-Phe-Arg-NMec the plasma CP was identified as cathepsin B or a cathepsin B-like proteinase (CBP). Kinetic studies revealed that dilution and competition with substrate effects reversible dissociation of CBP from complexes with plasma inhibitors that are most probably the kininogens. The dissociation of CBP was confirmed by gel chromatographic fractionation of the plasma proteins. The results suggest that active CBP can easily dissociate from its plasma inhibitor complexes in vivo and may be involved in pathogenetic extracellular proteolysis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3202966

Source DB:  PubMed          Journal:  Biol Chem Hoppe Seyler        ISSN: 0177-3593


  10 in total

1.  Purification and characterization of high molecular mass and low molecular mass cystatin from goat brain.

Authors:  Sadia Sumbul; Bilqees Bano
Journal:  Neurochem Res       Date:  2006-10-25       Impact factor: 3.996

Review 2.  The early and late processing of lysosomal enzymes: proteolysis and compartmentation.

Authors:  A Hasilik
Journal:  Experientia       Date:  1992-02-15

3.  Cathepsin B and cysteine proteinase inhibitors in human lung cancer cell lines.

Authors:  H H Heidtmann; U Salge; M Abrahamson; M Bencina; L Kastelic; N Kopitar-Jerala; V Turk; T T Lah
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

4.  Cleavage of plasma high molecular weight kininogen in surgical ICU patients.

Authors:  T S Karlsrud; L Buø; A O Aasen; H T Johansen
Journal:  Intensive Care Med       Date:  1996-08       Impact factor: 17.440

5.  Comparison of guanidine hydrochloride (GdnHCl) and urea denaturation on inactivation and unfolding of human placental cystatin (HPC).

Authors:  Fouzia Rashid; Sandeep Sharma; Bilqees Bano
Journal:  Protein J       Date:  2005-07       Impact factor: 2.371

6.  Modification of cystatin C activity by bacterial proteinases and neutrophil elastase in periodontitis.

Authors:  M Abrahamson; M Wikström; J Potempa; S Renvert; A Hall
Journal:  Mol Pathol       Date:  1997-12

7.  Demonstration of cathepsins B, H and L in xenografts of normal and Duchenne-muscular-dystrophy muscles transplanted into nude mice.

Authors:  A Takeda; T Jimi; Y Wakayama; N Misugi; S Miyake; T Kumagai
Journal:  Biochem J       Date:  1992-12-01       Impact factor: 3.857

8.  Cathepsin B in the rat eye.

Authors:  Johan Wassélius; Hanna Wallin; Magnus Abrahamson; Berndt Ehinger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-10-28       Impact factor: 3.117

9.  Human cystatin C. role of the N-terminal segment in the inhibition of human cysteine proteinases and in its inactivation by leucocyte elastase.

Authors:  M Abrahamson; R W Mason; H Hansson; D J Buttle; A Grubb; K Ohlsson
Journal:  Biochem J       Date:  1991-02-01       Impact factor: 3.857

10.  Cathepsin B fraction active at physiological pH of 7.5 is of prognostic significance in squamous cell carcinoma of human lung.

Authors:  B Werle; B Jülke; T Lah; E Spiess; W Ebert
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.